Cooley advised Cholesgen on the deal. Cholesgen (Shanghai) Co.Ltd. announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with...
You must be a Standard 1 Year member to access this content.
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
You must be a Standard 1 Year member to access this content.
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
You must be a Standard 1 Year member to access this content.
Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal. Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally...
You must be a Standard 1 Year member to access this content.
